Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review

Publikation: Bidrag til tidsskriftReviewForskningpeer review


  1. COPD patients prescribed inhaled corticosteroid in general practice: Based on disease characteristics according to guidelines?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Predictors of accelerated FEV1 decline in adults with airflow limitation-Findings from the Health2006 cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Predictors of COPD in symptomatic smokers and ex-smokers seen in primary care

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Oral prednisolone for 4 days does not increase exercise tolerance in men with COPD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

To provide an update on efficacy and safety of antibiotic treatments for stable non-cystic fibrosis (CF) bronchiectasis (BE). Systematic review based on the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines was done. Twenty-six studies (1.898 patients) fulfilled the inclusion criteria. Studies of inhaled tobramycin have revealed conflicting results regarding quality of life (QoL), exacerbations and admissions, but may result in sputum cultures negative for Pseudomonas aeruginosa, whereas studies investigating the effect of inhaled gentamycin have shown positive effects on sputum bacterial density, decrease in sputum cultures positive for P. aeruginosa, QoL and exacerbation rate, but no improvement in forced expiratory volume in first second (FEV1). Oral azithromycin can reduce exacerbations, together with minor improvements in QoL and FEV1 Furthermore, oral erythromycin reduces exacerbations, but has no effect on lung function, symptoms or QoL. Inhaled ciprofloxacin may reduce P. aeruginosa in sputum cultures, but without changes in lung function, exacerbations or QoL. Although with limited evidence, inhaled colistin may have effects on P. aeruginosa density, exacerbations and QoL, whereas studies on aztreonam revealed no significant clinical improvements in the outcomes of interest, including exacerbation rate. Adverse events, including bronchospasm, have been reported in association with tobramycin and aztreonam. Several antibiotic treatment regimens have been shown to improve QoL and exacerbation rate, whereas findings regarding sputum production, lung function and admissions have been conflicting. Evidence-based treatment algorithms for antibiotic treatment of stable non-CF BE will have to await large-scale, long-term controlled studies.

TidsskriftChronic Respiratory Disease
Udgave nummer2
Sider (fra-til)174-186
StatusUdgivet - 2017

ID: 48349860